» Articles » PMID: 36280866

Narrative Review on Century of Respiratory Pandemics from Spanish Flu to COVID-19 and Impact of Nanotechnology on COVID-19 Diagnosis and Immune System Boosting

Overview
Journal Virol J
Publisher Biomed Central
Specialty Microbiology
Date 2022 Oct 25
PMID 36280866
Authors
Affiliations
Soon will be listed here.
Abstract

The rise of the highly lethal severe acute respiratory syndrome-2 (SARS-2) as corona virus 2019 (COVID-19) reminded us of the history of other pandemics that happened in the last century (Spanish flu) and stayed in the current century, which include Severe-Acute-Respiratory-Syndrome (SARS), Middle-East-Respiratory-Syndrome (MERS), Corona Virus 2019 (COVID-19). We review in this report the newest findings and data on the origin of pandemic respiratory viral diseases, reservoirs, and transmission modes. We analyzed viral adaption needed for host switch and determinants of pathogenicity, causative factors of pandemic viruses, and symptoms and clinical manifestations. After that, we concluded the host factors associated with pandemics morbidity and mortality (immune responses and immunopathology, ages, and effect of pandemics on pregnancy). Additionally, we focused on the burdens of COVID-19, non-pharmaceutical interventions (quarantine, mass gatherings, facemasks, and hygiene), and medical interventions (antiviral therapies and vaccines). Finally, we investigated the nanotechnology between COVID-19 analysis and immune system boosting (Nanoparticles (NPs), antimicrobial NPs as antivirals and immune cytokines). This review presents insights about using nanomaterials to treat COVID-19, improve the bioavailability of the abused drugs, diminish their toxicity, and improve their performance.

Citing Articles

Role of tomography in the screening at the emergency room during pandemics.

Albuquerque M, DOliveira Vieira R, Eduardo Fonteles Ritt L Clinics (Sao Paulo). 2024; 80:100559.

PMID: 39671880 PMC: 11699805. DOI: 10.1016/j.clinsp.2024.100559.


25 Years Responding to Respiratory and Other Viruses with Mass Spectrometry.

Downard K Mass Spectrom (Tokyo). 2023; 12(1):A0136.

PMID: 38053835 PMC: 10694638. DOI: 10.5702/massspectrometry.A0136.


Severity of COVID-19 in Patients with Diarrhoea: A Systematic Review and Meta-Analysis.

Dhakal S, Charoen P, Pan-Ngum W, Luvira V, Sivakorn C, Hanboonkunupakarn B Trop Med Infect Dis. 2023; 8(2).

PMID: 36828500 PMC: 9966065. DOI: 10.3390/tropicalmed8020084.

References
1.
Singh H, Jakhar R, Sehrawat N . Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon. 2020; 6(11):e05528. PMC: 7667438. DOI: 10.1016/j.heliyon.2020.e05528. View

2.
Schotsaert M, Saelens X, Leroux-Roels G . Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines. 2012; 11(8):949-62. DOI: 10.1586/erv.12.71. View

3.
Tan S, Ganji G, Paeper B, Proll S, Katze M . Systems biology and the host response to viral infection. Nat Biotechnol. 2007; 25(12):1383-9. PMC: 7097743. DOI: 10.1038/nbt1207-1383. View

4.
Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

5.
Chan-Yeung M, Xu R . SARS: epidemiology. Respirology. 2004; 8 Suppl:S9-14. PMC: 7169193. DOI: 10.1046/j.1440-1843.2003.00518.x. View